Show simple item record

dc.contributor.authorElgebaly, Salwa A.
dc.contributor.authorTodd, Robert
dc.contributor.authorKreutzer, Donald L.
dc.contributor.authorChristenson, Robert
dc.contributor.authorEl-Khazragy, Nashwa
dc.contributor.authorArafa, Reem K.
dc.contributor.authorRabie, Mostafa A.
dc.contributor.authorMohamed, Ahmed F.
dc.contributor.authorAhmed, Lamiaa A.
dc.contributor.authorEl Sayed, Nesrine S.
dc.date.accessioned2021-04-05T19:44:01Z
dc.date.available2021-04-05T19:44:01Z
dc.date.issued2021-03-30
dc.identifier.urihttp://hdl.handle.net/10713/15090
dc.description.abstractBackground: Cyclocreatine phosphate (CCrP) is a potent bioenergetic cardioprotective com-pound known to preserve high levels of cellular adenosine triphosphate during ischemia. Using the standard Isoproterenol (ISO) rat model of heart failure (HF), we recently demonstrated that the administration of CCrP prevented the development of HF by markedly reducing cardiac remodeling (fibrosis and collagen deposition) and maintaining normal ejection fraction and heart weight, as well as physical activity. The novel inflammatory mediator, Nourin is a 3-KDa formyl peptide rapidly released by ischemic myocardium and is associated with post-ischemic cardiac inflammation. We reported that the Nourin-associated miR-137 (marker of cell damage) and miR-106b-5p (marker of inflammation) are significantly upregulated in unstable angina patients and patients with acute myocardial infarction, but not in healthy subjects. Objectives: To test the hypothesis that Nourin-associated miR-137 and miR-106b-5p are upregulated in ISO-induced “HF rats” and that the administration of CCrP prevents myocardial injury (MI) and reduces Nourin gene expression in “non-HF rats”. Methods: 25 male Wistar rats (180–220 g) were used: ISO/saline (n = 6), ISO/CCrP (0.8 g/kg/day) (n = 5), control/saline (n = 5), and control/CCrP (0.8 g/kg/day) (n = 4). In a limited study, CCrP at a lower dose of 0.4 g/kg/day (n = 3) and a higher dose of 1.2 g/kg/day (n = 2) were also tested. The Rats were injected SC with ISO for two consecutive days at doses of 85 and 170 mg/kg/day, respectively, then allowed to survive for an additional two weeks. CCrP and saline were injected IP (1 mL) 24 h and 1 h before first ISO administration, then daily for two weeks. Serum CK-MB (U/L) was measured 24 h after the second ISO injection to confirm myocardial injury. After 14 days, gene expression levels of miR-137 and miR-106b-5p were measured in serum samples using quantitative real-time PCR (qPCR). Results: While high levels of CK-MB were detected after 24 h in the ISO/saline rats indicative of MI, the ISO/CCrP rats showed normal CK-MB levels, supporting prevention of MI by CCrP. After 14 days, gene expression profiles showed significant upregulation of miR-137 and miR-106b-5p by 8.6-fold and 8.7-fold increase, respectively, in the ISO/saline rats, “HF rats,” compared to the control/saline group. On the contrary, CCrP treatment at 0.8 g/kg/day markedly reduced gene expression of miR-137 by 75% and of miR-106b-5p by 44% in the ISO/CCrP rats, “non-HF rats,” compared to the ISO/Saline rats, “HF rats.” Additionally, healthy rats treated with CCrP for 14 days showed no toxicity in heart, liver, and renal function. Conclusions: Results suggest a role of Nourin-associated miR-137 and miR-106b-5p in the pathogenesis of HF and that CCrP treatment prevented ischemic injury in “non-HF rats” and significantly reduced Nourin gene expression levels in a dose–response manner. The Nourin gene-based mRNAs may, therefore, potentially be used as monitoring markers of drug therapy response in HF, and CCrP—as a novel preventive therapy of HF due to ischemia. © 2021 by the authors.en_US
dc.description.sponsorshipAcademy of Scientific Research and Technologyen_US
dc.description.urihttps://doi.org/10.3390/ijms22073575en_US
dc.language.isoenen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofInternational Journal of Molecular Sciencesen_US
dc.subjectCardioprotectionen_US
dc.subjectCyclocreatine phosphateen_US
dc.subjectDrug therapy responseen_US
dc.subjectHeart failureen_US
dc.subjectInflammatory mediatorsen_US
dc.subjectMiR-137 and miR-106b-5pen_US
dc.subjectMonitoring biomarkeren_US
dc.subjectMyocardial ischemiaen_US
dc.subjectNourinen_US
dc.titleNourin-associated mirnas: Novel inflammatory monitoring markers for cyclocreatine phosphate therapy in heart failureen_US
dc.typeArticleen_US
dc.identifier.doi10.3390/ijms22073575
dc.source.volume22
dc.source.issue7


This item appears in the following Collection(s)

Show simple item record